Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-06-2016 | Case Report

Dysfibrinogenemia with Subgaleal Hematoma: An Unusual Presentation

Authors: Manika Khare, Vijay Kumar, Sadhna Marwah, A. S. Nigam, Gurdeep Buxi

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Excerpt

Dysfibrinogenemia is a rare familial disorder characterized by abnormal fibrinogen, which results in defective fibrin clot formation. Dysfibrinogenemia can be congenital or acquired. It is inherited as an autosomal dominant trait with high levels of penetrance. It can diverge in severity from asymptomatic to abnormal clinical bleeding and thrombotic tendency [1]. Subgaleal hematoma is a very unusual presentation in dysfibrinogenemia. …

Powell JS, Rodgers GM (2013) Inherited coagulation disorders. In: Greer JP, Arber DA, Glader B, List AF, Means RT, Paraskevas F, Rodger GM (eds) Wintrobe’s clinical hematology, 13th edn. Wolter Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, pp 1122–1217

Hayes T (2002) Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 126:1387–1390PubMed

Kotlin R, Reicheltova Z, Maly M et al (2009) Two cases of congenital dysfibrinogenemia associated with thrombosis—Fibrinogen Praha III and Fibrinogen Plzen. Thromb Haemost 102:479–486PubMed

Asselta R, Duga S, Tenchini ML (2006) The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 4:2115–2129CrossRefPubMed

Francis JL, Armstrong DJ (1982) Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 35:667–672CrossRefPubMedPubMedCentral

Gralnick HR, Givelber H, Abrams E (1978) Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. NEJM 299:221–226CrossRefPubMed

Levy J, Pettei MJ, Weitz JI (1987) Dysfibrinogenemia in obstructive liver disease. J Pediatr Gastroenterol Nutr 6:967–970CrossRefPubMed

Dear A, Brennan SO, Sheat MJ, Faed JM, George PM (2007) Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain. Haematologica 92:e111–e117CrossRefPubMed

O’Kane MJ, Wisdom GB, Desai ZR, Archbold GP (1994) Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin. J Clin Pathol 47:266–268CrossRefPubMedPubMedCentral

10.

Casini A, Blondon M, Lebreton A et al (2015) Natural history of patients with congenital dysfibrinogenemia. Blood 125(3):553–561CrossRefPubMedPubMedCentral

11.

Cunningham MT, Brandt JT, Laposata M, Olson JD (2002) Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 126:499–505PubMed

12.

Haverkate F, Samama M (1995) Familial dysfibrinogenemia and thrombophilia: report on a study of the SSC subcommittee of Fibrinogen. Thromb Haemost 73:151–161PubMed

13.

Blomback B (1958) Studies on the action of thrombic enzymes on bovine fibrinogen as measured by N-terminal analysis. Arkiv Kemi 12:321–335

14.

Ashby MA, Lazarchick J (1986) Case report: acquired dysfibrinogenemia secondary to mithramycin toxicity. Am J Med Sci 292:53–55CrossRefPubMed

15.

Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P (2015) Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost 13(6):909–919CrossRefPubMed

16.

Cunningham Mark T, Brandt John T, Laposata Michael, Olson John D (2002) Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 126:499–505PubMed

Title: Dysfibrinogenemia with Subgaleal Hematoma: An Unusual Presentation
Authors: Manika Khare
Vijay Kumar
Sadhna Marwah
A. S. Nigam
Gurdeep Buxi
Publication date: 01-06-2016
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-015-0606-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2016

New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia

Familial Hemophagocytic Lymphohistiocytosis due to Mutation of UNC13D Gene

Delayed Serological Transfusion Reaction After Platelet Transfusion Due to Anti-e

Avascular Necrosis of Head of Femur in Dyskeratosis Congenita - A Rare Presentation

“Red Hand Syndrome” Due to Cytarabine in a Case of Mantle Cell Lymphoma

Mixed Phenotypic Acute Leukemia Presenting as Mediastinal Mass-2 Cases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer